Approaches to improve development methods for therapeutic cancer vaccines

Ogi, Chizuru; Aruga, Atsushi

doi:10.1016/j.imlet.2015.02.010

Cited by 6 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…cells through vaccination to activate T-cell responses and kill tumor cells, thus achieving precision treatment [1][2][3]. Peptide vaccines have been extensively studied, because they are simple, safe, and economical [4]. However, due to their unique peptide epitopes, low molecular weights, easy degradation, and short half-lives, peptide vaccines have two basic limitations: low immunogenicity and major histocompatibility complex (MHC) restriction [5,6].…”

mentioning

confidence: 99%

Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

Zhang¹,

Yuan²,

Shu³

et al. 2019

Cancer Immunol Immunother

View full text Add to dashboard Cite

Development of personalized cancer vaccines based on neoantigens has become a new direction in cancer immunotherapy. Two forms of cancer vaccines have been widely studied: tumor-associated antigen (including proteins, peptides, or tumor lysates)-pulsed dendritic cell (DC) vaccines and protein-or peptide-adjuvant vaccines. However, different immune modalities may produce different therapeutic effects and immune responses when the same antigen is used. Therefore, it is necessary to choose a more effective neoantigen vaccination method. In this study, we compared the differences in immune and anti-tumor effects between neoantigen-pulsed DC vaccines and neoantigen-adjuvant vaccines using murine lung carcinoma (LL2) candidate neoantigens. The enzyme-linked immunospot (ELISPOT) assay showed that 4/6 of the neoantigen-adjuvant vaccines and 6/6 of the neoantigen-pulsed DC vaccines induced strong T-cell immune responses. Also, 2/6 of the neoantigen-adjuvant vaccines and 5/6 of the neoantigen-pulsed DC vaccines exhibited potent anti-tumor effects. The results indicated that the neoantigen-pulsed DC vaccines were superior to the neoantigen-adjuvant vaccines in both activating immune responses and inhibiting tumor growth. Our fundings provide an experimental basis for the selection of immune modalities for the use of neoantigens in individualized tumor immunotherapies.

show abstract

mentioning

confidence: 99%

Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

Zhang¹,

Yuan²,

Shu³

et al. 2019

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…It was found that, in both NV and MV, payloads were partly released in the endosome-lysosome system and partly escaped from the endosome-lysosome system into the cytosol for cross-presentation ( Figures S3 C and S3D). This result demonstrated that antigens in both NVs and MVs can be presented by MHC I and MHC II pathways, and thus stimulate both CD4 + and CD8 + cancer-specific T cells 4 , 13 , 14 , 23 , 24 , 25 , 26 , 27 ( Figure S1 B).…”

Section: Resultsmentioning

confidence: 86%

Across-cancer specific immune responses induced by nanovaccines or microvaccines to prevent different cancers and cancer metastasis

Diao¹,

Ma²,

Cheng³

et al. 2022

iScience

View full text Add to dashboard Cite

“…Pancreas-specific transgene expression in spontaneous PC mice model and either protein fragments or intact proteins as immunogens could address these limitations faced in this field, thereby increasing the cancer vaccine efficacy. Additionally, selection of PC patient based on both tumor stage and tumor infiltrating lymphocytes (TILs) like CD8 + and PD-1 + T-cells could further increase the response to cancer vaccines [101].…”

Section: Limitations Of Current Strategies Perspectives and Conclmentioning

confidence: 99%

Emerging trends in the immunotherapy of pancreatic cancer

et al. 2018

View full text Add to dashboard Cite

Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in the U.S., claiming approximately 43,000 lives every year. Much like other solid tumors, PC evades the host immune surveillance by manipulating immune cells to establish an immunosuppressive tumor microenvironment (TME). Therefore, targeting and reinstating the patient's immune system could serve as a powerful therapeutic tool. Indeed, immunotherapy has emerged in recent years as a potential adjunct treatment for solid tumors including PC. Immunotherapy modulates the host's immune response to tumor-associated antigens (TAAs), eradicates cancer cells by reducing host tolerance to TAAs and provides both short- and long-term protection against the disease. Passive immunotherapies like monoclonal antibodies or engineered T-cell based therapies directly target tumor cells by recognizing TAAs. Active immunotherapies, like cancer vaccines, on the other hand elicit a long-lasting immune response via activation of the patient's immune cells against cancer cells. Several immunotherapy strategies have been tested for anti-tumor responses alone and in combination with standard care in multiple preclinical and clinical studies. In this review, we discuss various immunotherapy strategies used currently and their efficacy in abrogating self-antigen tolerance and immunosuppression, as well as their ability to eradicate PC.

show abstract

Approaches to improve development methods for therapeutic cancer vaccines

Cited by 6 publications

References 39 publications

Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models

Across-cancer specific immune responses induced by nanovaccines or microvaccines to prevent different cancers and cancer metastasis

Emerging trends in the immunotherapy of pancreatic cancer

Contact Info

Product

Resources

About